Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A

অনুরূপ উপাদানগুলি

• Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1
  অনুযায়ী: Kohrt, Holbrook, অন্যান্য
  প্রকাশিত: (2013)
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
  অনুযায়ী: Herbst, Roy S., অন্যান্য
  প্রকাশিত: (2014)
• Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer
  অনুযায়ী: Xiao, Yuanyuan, অন্যান্য
  প্রকাশিত: (2014)
• P13. Intra-tumoral and surrogate immune responses in patients treated with the engineered anti-PD-L1 antibody (MPDL3280A)
  অনুযায়ী: Kowanetz, M, অন্যান্য
  প্রকাশিত: (2014)
• Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)
  অনুযায়ী: Powles, Thomas, অন্যান্য
  প্রকাশিত: (2015)